A nova pesquisa da Cleveland Clinic mostra pela primeira vez que o ibrutinib (ibrutinib) aprovado pela FDA para linfoma e leucemia também pode ajudar a tratar os tumores cerebrais mais comuns e mortais e pode um dia ser usado em pacientes com glioblastoma e melhorar as taxas de sobrevivência.
De acordo com o relatório da American Brain Tumor Association, a taxa de sobrevivência do glioblastoma é muito baixa e a sobrevida média dos pacientes que recebem tratamento padrão é inferior a 15 meses. Glioblastoma é o tumor cerebral primário mais mortal e é altamente resistente aos tratamentos atuais. Há uma necessidade urgente de fornecer a esses pacientes novos tratamentos o mais rápido possível.
In an earlier study, Bao and colleagues found that glioma stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain tumores in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
